Aflibercept is a medicine used to treat eye diseases like wet macular degeneration and diabetic eye disease. A doctor gives it as a shot into the eye, usually every few weeks to every few months. It works by stopping leaky, unhealthy blood vessels from growing in the back of the eye.
Every report comes from a Lived member, sent anonymously.
Have you tried Eylea (Aflibercept) for Wet Macular Degeneration?
Aflibercept, best known by the brand name Eylea, is a prescription medicine injected into the eye to treat conditions in which abnormal or leaky blood vessels damage the retina, the light-sensing layer at the back of the eye. It is approved for wet age-related macular degeneration (AMD), swelling of the macula (the central part of the retina used for reading and recognizing faces) caused by diabetes or by a blocked retinal vein, and diabetic retinopathy, the blood vessel damage diabetes causes in the retina. Eylea HD is a higher-dose version of the same medicine for the same adult conditions, designed to allow longer gaps between injections. Pavblu and several other approved biosimilars (versions shown to work the same way as the original) are also available for adults. The standard Eylea product is also used in a much smaller dose for premature babies with retinopathy of prematurity (ROP), a condition in which blood vessels in an immature retina grow abnormally. Zaltrap (ziv-aflibercept) is a related but separate product given into a vein alongside chemotherapy for colorectal cancer. It is not an eye treatment and is not covered here.
VEGF (vascular endothelial growth factor) is a natural signal that tells blood vessels to grow and makes them more permeable. In wet AMD and diabetic eye disease, too much VEGF drives fragile new vessels to form under or within the retina and makes existing vessels leak fluid and blood. That fluid swells the macula and blurs or distorts central vision, and over time it can scar the retina permanently. Aflibercept is a lab-made protein that acts as a decoy, catching VEGF and a related signal called placental growth factor before they can reach their receptors. With less signal, abnormal vessels leak less and grow less, the swelling can settle, and vision is protected and sometimes partly improves. The effect wears off gradually, which is why injections are repeated.
Aflibercept is given only by an eye specialist, as an injection into the vitreous, the clear gel inside the eye. The eye is numbed with drops or gel and cleaned with antiseptic, and a very fine needle is used. The injection itself takes seconds; most people feel pressure rather than sharp pain. The eye pressure is checked afterward because it can rise briefly. Treatment usually starts with injections about once a month for the first few doses. For standard Eylea in wet AMD or diabetic eye disease, the gap then typically widens to every 8 weeks, although some eyes need monthly injections and some can stretch further. Eylea HD uses a larger dose, so after three monthly doses the gap is often 8 to 16 weeks. Macular swelling from a blocked vein is usually treated monthly with standard Eylea. Infants with ROP receive a single small dose in each affected eye, repeated only if needed. Vision may be blurry for a few hours after the injection and the dilated eye exam that often comes with it, so arrange a ride home and do not drive until your sight has recovered.
The most common effects are related to the injection: a red patch of bleeding on the white of the eye, mild eye pain or a gritty feeling, and new floaters (small specks drifting across your vision). These usually clear within days to a couple of weeks. Over many injections, some people develop a cataract or a lasting rise in eye pressure, which is why pressure is checked regularly. Serious problems are uncommon, occurring in fewer than 1 in 1,000 injections in clinical trials, but they can threaten sight. They include infection inside the eye (endophthalmitis), a detached retina and inflammation of the retinal blood vessels. In the days after an injection, call your eye doctor right away if the eye becomes increasingly red, painful or sensitive to light, or if your vision gets worse or changes, such as a shadow, curtain or sudden shower of floaters. Allergic reactions such as rash, itching or hives are rare.
Aflibercept is not injected if there is an infection in or around the eye, such as an eyelid or eye surface infection, or active inflammation inside the eye. Mention any red, sore or crusted eye before your appointment; the injection may be postponed until it clears. It should also not be used by anyone with a known allergy to aflibercept. Because blocking VEGF can affect blood vessels elsewhere, there is a possible small risk of stroke or heart attack after these injections. In clinical trials the rates were similar to those in people receiving comparison treatments, but your doctor should know about any recent stroke, heart attack or circulation problems. Aflibercept may harm a developing baby. People who could become pregnant are advised to use effective birth control before the first injection, during treatment and for at least 3 months after the last one, and it is not recommended while breastfeeding. Few drug interactions are known because so little reaches the bloodstream, but keep your eye team informed about blood thinners and other medicines.
Aflibercept is usually a long-term treatment rather than a short course. The main goal is to stop vision from getting worse; many people also regain some sight in the first months, but damage already done to the retina may not reverse. In large trials in wet AMD, standard Eylea every 8 weeks protected vision about as well as monthly injections of ranibizumab (Lucentis), an older anti-VEGF medicine. Each visit typically includes a vision check and a retinal scan (optical coherence tomography, or OCT, a quick painless image that measures fluid in the retina). These results guide whether the next injection comes sooner or later. Stopping or stretching treatment too far can allow fluid and vision loss to return, so keeping appointments matters even when your vision seems stable. For diabetic eye disease, controlling blood sugar and blood pressure still matters alongside the injections. Premature babies treated for ROP need frequent eye exams for months afterward, because the abnormal vessels can return and further injections or laser treatment may be needed.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Eylea (Aflibercept), what you've noticed, or ask the community a question.